Lindy Biosciences, Inc.

Lindy Biosciences, Inc. is a biotechnology startup founded in 2017 that is making significant strides in the field of protein therapeutic formulations. The company's core technology, Microglassification™, sets it apart by creating spherical, dense, stable particles of therapeutic proteins. These particles offer advantages for long-term storage and can be incorporated into various drug delivery formulations for different uses, including high-concentration delivery of antibodies, sustained/controlled release, and dry powder pulmonary delivery.

With its slogan "Advanced Formulation Technologies for Better Biotherapeutics," Lindy Biosciences has attracted significant attention, including a recent $3.20M Series B investment in March 2022. The investment was led by Good Growth Capital and IAG Capital Partners, highlighting the confidence that notable investors have in the company's potential. In light of these developments, Lindy Biosciences is well-positioned to continue its growth trajectory and make valuable contributions to the biotechnology industry.

Based in the United States, Lindy Biosciences is at the forefront of advancements in therapeutic protein formulations, promising a positive impact on the future of biotherapeutics and drug delivery. With its innovative approach and strong support from investors, the company is a compelling presence in the biotechnology landscape, and its progress is worth watching closely.